Cancer Research Horizons and biotech company Turbine have announced a partnership to solve complex diseases. The partnership will utilise Turbine’s Simulated Cells platform to identify target patient populations who could benefit from CDC7 inhibitor therapy with Cancer Research Horizons’ lead compound CRT’2199. CRT’2199 originates from Cancer Research Horizons’ Therapeutic Innovation. CDC7 is a protein which […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
